Arcturus Therapeutics Holdings (ARCT) Enterprise Value (2018 - 2026)

Arcturus Therapeutics Holdings has reported Enterprise Value for 9 years, with the latest figure at -$211.4 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 17.25% year-over-year to -$211.4 million; the trailing twelve-month figure through Mar 2026 stood at -$211.4 million (up 17.25% YoY), and the FY2025 full-year result was -$230.9 million, up 33.82% from the prior year.
• Enterprise Value for Q1 2026 stood at -$211.4 million, up from -$230.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$211.4 million in Q1 2026, with the low at -$391.9 million in Q4 2022.
• Historically, Enterprise Value has averaged -$295.7 million across 5 years, with a median of -$311.9 million in 2023.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 42.57% — and 2023, when it slumped 31.24%.
• Arcturus Therapeutics Holdings' Enterprise Value stood at -$391.9 million in 2022, then increased by 11.45% to -$347.0 million in 2023, then slipped by 0.55% to -$348.9 million in 2024, then surged by 33.82% to -$230.9 million in 2025, then gained by 8.46% to -$211.4 million in 2026.
• The last three Enterprise Value figures came in at -$211.4 million (Q1 2026), -$230.9 million (Q4 2025), and -$235.4 million (Q3 2025), per Business Quant data.